- Home
- UNB vs CHRS Comparison
UNB vs CHRS Comparison
Compare UNB & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNB
- CHRS
- Stock Information
- Founded
- UNB 1891
- CHRS 2010
- Country
- UNB United States
- CHRS United States
- Employees
- UNB N/A
- CHRS N/A
- Industry
- UNB Major Banks
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UNB Finance
- CHRS Health Care
- Exchange
- UNB Nasdaq
- CHRS Nasdaq
- Market Cap
- UNB 167.6M
- CHRS 134.4M
- IPO Year
- UNB 1998
- CHRS 2014
- Fundamental
- Price
- UNB $28.90
- CHRS $1.07
- Analyst Decision
- UNB
- CHRS Strong Buy
- Analyst Count
- UNB 0
- CHRS 4
- Target Price
- UNB N/A
- CHRS $5.38
- AVG Volume (30 Days)
- UNB 6.0K
- CHRS 2.0M
- Earning Date
- UNB 03-04-2025
- CHRS 03-12-2025
- Dividend Yield
- UNB 4.98%
- CHRS N/A
- EPS Growth
- UNB N/A
- CHRS N/A
- EPS
- UNB 1.94
- CHRS N/A
- Revenue
- UNB $47,157,000.00
- CHRS $304,340,000.00
- Revenue This Year
- UNB N/A
- CHRS $2.07
- Revenue Next Year
- UNB N/A
- CHRS N/A
- P/E Ratio
- UNB $14.90
- CHRS N/A
- Revenue Growth
- UNB N/A
- CHRS 44.19
- 52 Week Low
- UNB $21.00
- CHRS $0.66
- 52 Week High
- UNB $37.70
- CHRS $2.65
- Technical
- Relative Strength Index (RSI)
- UNB 36.26
- CHRS 39.03
- Support Level
- UNB $31.70
- CHRS $1.06
- Resistance Level
- UNB $35.00
- CHRS $1.16
- Average True Range (ATR)
- UNB 1.58
- CHRS 0.08
- MACD
- UNB -0.30
- CHRS 0.00
- Stochastic Oscillator
- UNB 10.88
- CHRS 5.56
About UNB Union Bankshares Inc.
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group. Geographically, all the business activity is functioned through the United States.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.